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Inositoylated Platelet-Activating Factor (Ino-C2-PAF)
Modulates Dynamic Lymphocyte–Endothelial Cell
Interactions and Alleviates Psoriasis-Like Skin
Inflammation in Two Complementary Mouse Models
Susann Forkel1,5, Margarete Scho¨n1,5, Annette Hildmann2, Anna Claen1,3, Swen-Malte John3,4, Kerstin
Danker2 and Michael P. Scho¨n1,3
Psoriasis, a tumor necrosis factor alpha (TNFa)-governed inflammatory disorder with prominent dysregulation of
cutaneous vascular functions, has evolved into a model disorder for studying anti-inflammatory therapies. We
present experimental in vitro and in vivo data on 1-O-octadecyl-2-O-(2-(myo-inositolyl)-ethyl)-sn-glycero-3-(R/S)-
phosphatidyl-choline (Ino-C2-PAF), the lead compound of a class of synthetic glycosylated phospholipids, in
anti-inflammatory therapy. Ino-C2-PAF strongly induced apoptosis only in TNFa-stimulated, but not in untreated
human vascular endothelial cells. Moreover, TNFa-induced endothelial adhesion molecules that mediated the
rolling and firm adhesion of leukocytes (vascular cell adhesion protein-1 (VCAM-1), E-selectin, and ICAM-1) were
selectively downregulated by Ino-C2-PAF. Similarly, expression of L-selectin, VCAM-1 receptor a4b1 integrin , and
lymphocyte function-associated antigen-1 on human peripheral blood mononuclear cells was reduced without
induction of apoptosis. Functionally, these changes were accompanied by significant impairment of rolling and
adhesion of human peripheral blood lymphocytes on TNFa-activated endothelial cells in a dynamic flow chamber
system. When the therapeutic potential of Ino-C2-PAF was assessed in two complementary mouse models
of psoriasis, K5.hTGFb1 transgenic and JunB/c-Jun-deficient mice, Ino-C2-PAF led to significant alleviation of
the clinical symptoms and normalized the pathological cutaneous changes including vascularization. There were
no overt adverse effects. These findings suggested that Ino-C2-PAF is a potential candidate in the therapy of
inflammatory skin diseases that include abnormal vascular functions.
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INTRODUCTION
Psoriasis is one of the best-studied inflammatory skin disorders
(Nickoloff and Nestle, 2004; Scho¨n and Boehncke, 2005;
Griffiths and Barker, 2007; Nestle et al., 2009) and several
animal models have helped to understand specific aspects of
psoriatic inflammation (Scho¨n, 2008; Wagner et al., 2010).
Targeting the functions of several key players is thought to be
efficacious in a preclinical or clinical setting (Svensson et al.,
2012). Among other alterations within the tumor necrosis
factor alpha (TNFa)-governed microenvironment, there are
prominent vascular changes, which may serve as a promising
therapeutic target (Heidenreich et al., 2009; Scho¨nthaler et al.,
2009; Zibert et al., 2011; Crawshaw et al., 2012; Singh et al.,
2013).
We report here to our knowledge a previously unreported
experimental in vitro and in vivo study of a synthetic platelet-
activating factor (PAF)–derived alkylphospholipid in inflam-
mation-related functions relevant to psoriasis.
Synthetic alkylphospholipids (APLs) are structurally derived
from PAF (Berkovic, 1998). Prototypes are edelfosine (ET-18-
OCH3) (Bosse et al., 1995; Mollinedo et al., 1997; Arthur and
Bittman, 1998; Gajate and Mollinedo, 2001) and miltefosine
(hexadecylphosphocholine) (Scho¨n et al., 1996; Clive et al.,
1999). Owing to their chemical structure, alkylphospholipids
become incorporated into cell membranes where they
interfere with signaling events and influence proliferation,
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survival, adhesion, migration, and cytokine production
(Mollinedo et al., 1997; Arthur and Bittman, 1998; Wieder
et al., 1999).
Glycosidated phospholipids are a group of alkylphospho-
lipids, which are formally characterized by the introduction
of monosaccharide-related moieties within the chemical
lead of Lyso-PAF (Mickeleit et al., 1998). One member, the
inositoylated platelet-activating factor (Ino-C2-PAF;
1-O-octadecyl-2-O-(2-(myo-inositolyl)-ethyl)-sn-glycero-3-
(R/S)-phosphatidyl-choline; Figure 1a), showed high efficacy
and low cytotoxicity, particularly in keratinocyte-derived
cell lines (Fischer et al., 2006; Danker et al., 2010). In vitro,
Ino-C2-PAF reduced proliferation and facilitated
differentiation of immortalized keratinocytes (Fischer et al.,
2006), and it downregulated genes associated with innate and
adaptive immune responses (Semini et al., 2011).
We demonstrate here a profound anti-inflammatory activity
of Ino-C2-PAF with special emphasis on dynamic
lymphocyte–endothelial cell interactions, the critical first step
in the recruitment cascade of circulating leukocytes to sites of
inflammation (Boehncke and Scho¨n, 2003; Scho¨n et al.,
2003). The relevance for chronic inflammatory processes
in vivo is demonstrated by therapeutic efficacy in two com-
plementary preclinical mouse models of psoriasis, namely,
K5.hTGFb1-transgenic mice (Li et al., 2004) and mice with
epidermal deficiency of c-Jun/JunB (Zenz et al., 2005).
RESULTS
Ino-C2-PAF induces TNFa-dependent apoptotic responses in
human endothelial cells
Given that psoriasis is characterized by a TNFa-governed
microenvironment, we first analyzed the responses of TNFa-
naı¨ve and TNFa-stimulated endothelial cells to Ino-C2-PAF
(Figure 1a). Although Ino-C2-PAF showed a dose-dependent
moderate inhibition of endothelial cell viability, there
were no significant differences regarding its effects on
TNFa-naı¨ve versus TNFa-stimulated human endothelial cells
(Figure 1b).
In marked contrast, however, Ino-C2-PAF induced profound
dose-dependent apoptotic responses in TNFa-stimulated
endothelial cells but not in their TNFa-naı¨ve counterparts.
As assessed by the generation of histone-bound DNA
fragments, apoptosis of TNFa-stimulated endothelial cells
increased by 2.3-fold at an Ino-C2-PAF concentration of
15mM and by 2.8-fold at a concentration of 20mM (Po0.01
compared with control cells in both cases), whereas TNFa-
naı¨ve cells did not enter into apoptosis (Figure 1c).
Ino-C2-PAF downregulates endothelial adhesion molecules
involved in leukocyte recruitment
Prompted by the unexpected observation that Ino-C2-PAF
induced apoptosis selectively in TNFa-stimulated endothelial
cells, we assessed other TNF-induced endothelial functions
relevant to inflammation, namely, rolling and adhesion of
leukocytes. This process is critically dependent on TNFa-
stimulated endothelial adhesion molecules including E-selec-
tin, vascular cell adhesion protein-1 (VCAM-1), and ICAM-1
(Scho¨n et al., 2003).
As determined by semiquantitative reverse-transcriptase–
PCR and densitometric analysis, TNFa (25 ng ml 1 for
4 hours) induced profound transcriptional induction of E-selec-
tin, VCAM-1, and ICAM-1. In addition, the inflammation-
relevant chemokines monocyte chemotactic protein-1 and
IL-8 were upregulated, whereas the expression of vascular
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Figure 1. Ino-C2-PAF induces apoptosis in tumor necrosis factor
alpha (TNFa)-stimulated endothelial cells. (a) Structure of Ino-C2-PAF
(1-O-octadecyl-2-O-(2-(myo-inositolyl)-ethyl)-sn-glycero-3-(R/S)-
phosphatidylcholine). (b) Subconfluent cultures of human endothelial cells
were stimulated with TNFa (25 ng ml1 for 4 hours, black bars) or left
untreated (gray bars). The effect of Ino-C2-PAF on cell viability was determined
by colorimetric MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium
bromide) assays after 24 hours. Values represent averages of sextuplicates
(±SD). (c) To assess apoptosis, histone-bound DNA fragments were
determined by ELISA. The effect of Ino-C2-PAF was assessed after 24 hours.
Values represent averages of triplicates (±SD). *Po0.05, **Po0.01,
***Po0.001 compared with the respective controls, determined by the two-
tailed t-test. All experiments were performed three times with similar results.
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endothelial cadherin (CD144) and vascular endothelial growth
factor was not affected (Figure 2a). Of note, Ino-C2-PAF led to
a clear dose-dependent suppression of the TNF-induced
upregulation of VCAM-1 by 60% at 20mM, while both
E-selectin and ICAM-1 were reduced by 40–50% (Figure 2a).
Transcription of monocyte chemotactic protein-1, vascular
endothelial growth factor, and vascular endothelial cadherin
(CD144) was not suppressed by Ino-C2-PAF.
The expression of endothelial adhesion molecules on the
protein level was determined by flow cytometry. Again,
endothelial cells were treated for 24 hours with Ino-C2-PAF
at different concentrations (up to 20mM) and activated with
TNFa (25 ng ml 1) for 4 hours. As expected, stimulation of
endothelial cells with TNFa alone resulted in a marked
upregulation of all three adhesion molecules (VCAM-1, from
mean fluorescence intensities (MFI)¼554 to MFI¼ 1,126
(induction by 2.0-fold); E-selectin, from MFI¼135 to
MFI¼1,061 (induction by 7.9-fold); ICAM-1, from MFI¼ 140
to MFI¼ 595 (induction by 4.25-fold)). When the cells were
exposed to Ino-C2-PAF (15mM), the TNFa-induced elevation of
VCAM-1 was reduced by 65% (Pr0.01; Supplementary
Figure S1a online) and the elevation of E-selectin was reduced
by 30% (P¼ 0.05; Supplementary Figure S1b online), although
the surface expression of ICAM-1 was not affected in a clear-
cut manner by Ino-C2-PAF (data not shown).
When the regulation of adhesion molecule expression by
Ino-C2-PAF was evaluated by immunofluorescence micro-
scopy as a second independent method, it was found that
neither E-selectin nor VCAM-1 were detectable in unstimu-
lated endothelial cells, whereas ICAM-1 was constitutively
expressed. Again, TNFa caused very strong upregulation of
both VCAM-1 and E-selectin, a function that was completely
abrogated by Ino-C2-PAF in case of VCAM-1 and was partially
decreased in case of E-selectin (Figure 2b).
Ino-C2-PAF reduces expression of lymphocyte adhesion
molecules
Activated endothelia are only one side of the coin when
immune-cell extravasation at sites of inflammation is con-
cerned. The other is circulating leukocytes expressing adhe-
sion receptors, such as L-selectin, VCAM-1 receptor a4b1
integrin, or lymphocyte function-associated antigen-1, which
interact with endothelial ligands. The net result of such
interactions is the recruitment of leukocytes to inflamed
tissues. To assess whether Ino-C2-PAF also affected human
leukocytes, peripheral blood mononuclear cells (PBMCs) were
isolated by density gradient centrifugation, treated with
Ino-C2-PAF (5, 15 or 30mM) for 2 hours, and surface expres-
sion of adhesion receptors was evaluated by flow cytometry
(Figure 3a).
Indeed, exposure of human PBMCs to Ino-C2-PAF resulted
in a marked dose-dependent downregulation of L-selectin
(CD62L) by 34% at a concentration of 5mM and by 86% at
30mM compared with untreated cells. A similar effect was
detected on CD11a, the alpha subunit of lymphocyte
function-associated antigen-1, where treatment with 30mM of
Ino-C2-PAF for 2 hours caused a reduction of surface expres-
sion by 86% compared with untreated control cells. Finally,
the expression of the a4 integrin subunit (CD49d), which is
part of the VCAM-1 receptor a4b1 integrin, was decreased by
B50% when treated with 30mM of Ino-C2-PAF (Figure 3a).
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Figure 2. Ino-C2-PAF decreases tumor necrosis factor alpha (TNFa)-induced
expression of E-selectin (CD62E), VCAM-1 (CD106), and ICAM-1 (CD54) on
endothelial cells. (a) Subconfluent endothelial cell cultures were stimulated
with 25 ng ml1 of TNFa for 4 hours after exposure to Ino-C2-PAF at the
indicated concentrations for 24 hours. The representative panels depict
semiquantitative reverse transcription–PCR to determine messenger RNA
expression. The experiments were performed three times with similar results.
(b) Endothelial cells were cultured in normal medium (upper row), stimulated
with TNFa (25ng ml1 for 4 hours; middle row), or treated with TNFa after
15mM Ino-C2-PAF for 24 hours (bottom row). Protein surface expression of
E-selectin (left column, red fluorescence) and vascular cell adhesion protein-1
(VCAM-1) (right column, green fluorescence) was determined by
immunofluorescence staining. Nuclei are visualized by 4,6-diamidino-2-
phenylindole (DAPI, blue color). Scale bar¼ 100mm.
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Of note, downregulation of cell surface–adhesion mole-
cules was effected without overt direct toxicity as evinced by
lack of significant apoptosis or necrosis of lymphocytes
following exposure to Ino-C2-PAF for 24 hours or even
48 hours (Figure 3b).
To mimic a potential therapeutic setting, the in vivo effect of
Ino-C2-PAF on lymphocyte adhesion receptors was investi-
gated using C57BL6/J mice. The mice (n¼ 3 per group) were
left untreated or received one, two, or three intraperitoneal
injections of 30 mg kg1 of Ino-C2-PAF. Repeated injections
were administered at 2-day intervals. Blood was collected
24 hours after the last injection. As determined by flow
cytometry, a single injection of Ino-C2-PAF decreased the
expression of L-selectin on PBMCs moderately by approxi-
mately one-third (n.s.), two or three injections resulted in a
significant reduction by approximately two-thirds compared
with the untreated controls (P¼ 0.05; Figure 3c). Ino-C2-PAF
had no significant impact on the expression of CD11a
(lymphocyte function-associated antigen-1) or CD49d (VCAM-
1 receptor a4b1 integrin) of PBMCs under these in vivo
conditions (not shown). The overall numbers of lymphocytes
(T-cell numbers ranged between 11 and 19% with no altera-
tions following in vivo treatment with Ino-C2-PAF) remained
stable during the observation period.
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Figure 3. Ino-C2-PAF downregulates lymphocyte adhesion molecules in vitro and in vivo, but does not induce apoptosis or necrosis. (a) Peripheral blood
mononuclear cells (PBMCs) were exposed to Ino-C2-PAF at the indicated concentrations for 2 hours and analyzed by flow cytometry for expression of
CD62L, CD49d, and CD11a on CD3þ T lymphocytes. Filled gray curves represent untreated cells (negative control), black curves indicate antigen expression after
Ino-C2-PAF treatment. The numbers depicted within the panels represent the actual mean fluorescence intensities (MFI). (b) Human PBMCs were untreated or
exposed to Ino-C2-PAF (20mM) for 24 hours or 48 hours. Apoptosis and necrosis were determined by flow cytometry after labeling with Annexin-V and propidium
iodide. The values shown represent the means of three independent experiments (±SEM). (c) C57BL/6 mice received intraperitoneal injections with vehicle
(control) or one to three injections with Ino-C2-PAF (30 mg kg1). At 24 hours after the last injection, CD62L expression on PBMCs was determined by flow
cytometry (n¼ 3 for each condition). *P¼0.05 compared with controls. The overall numbers of T cells remained stable during treatment with Ino-C2-PAF.
S Forkel et al.
Inositoylated Platelet-Activating Factor
www.jidonline.org 2513
Ino-C2-PAF impairs dynamic interactions of human lymphocytes
with TNFa-activated endothelial cells
To model the dynamics of lymphocyte–endothelial cell inter-
actions, a standardized flow chamber system exerting physio-
logical shear forces was used in two complementary settings.
In both settings, the immobile phase consisted of confluent
endothelial cell monolayers, which were either left untreated
or stimulated with TNFa (25 ng ml1), and the mobile phase
contained carboxyfluorescein diacetate N-succinimidyl ester-
labeled human PBMCs (Figure 4a). As expected (Oostingh
et al., 2007), PBMCs did not interact with unstimulated
endothelial cells, although TNFa induced pronounced
rolling and adhesion under flow conditions (Figure 4a and b).
In the first setting, TNFa stimulation of endothelial cells for
24 hours resulted in 43.7 (±18.4) rolling and 26.7 (±6.9)
firmly adhering PBMCs in standardized microscopic fields,
whereas pretreatment of endothelial cells with Ino-C2-PAF
suppressed this induction in a dose-dependent manner
(Figure 4b). At a concentration of 15mM, the number of rolling
cells was decreased by 53 to 20.3% per field and the number
of firmly adhering cells was reduced by 75 to 6.75% per field
(Po0.05; Figure 4b).
The second series of experiments was performed with
PBMCs pretreated with Ino-C2-PAF for 2 hours. PBMCs were
either left untreated or exposed to Ino-C2-PAF (5, 15, or 30mM;
higher end concentration owing to shorter incubation time).
In untreated PBMCs, 45.0 (±12.4) cells per field rolled on
the endothelial layer and 28.5 (±4.4) cells per field firmly
attached to it. At an Ino-C2-PAF concentration of 30mM, the
number of rolling cells was significantly lowered by 84% and
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Figure 4. Ino-C2-PAF impairs tumor necrosis factor alpha (TNFa)-dependent dynamic lymphocyte–endothelial cell interactions. (a) For flow chamber
experiments, endothelial cells were incubated with Ino-C2-PAF for 24 hours and stimulated with TNFa (25ng ml 1, 4 hours). Carboxyfluorescein diacetate
N-succinimidyl ester (CFDA-SE)-labeled peripheral blood mononuclear cells (PBMCs) were perfused with a shear flow of 1.12 ml per hour (10 min). Upper row,
phase contrast images of endothelial cells to demonstrate morphological integrity. Bottom row, representative images of adhering CFDA-SE-labeled lymphocytes
(examples indicated by arrows). (b) Rolling and adhesion of untreated PBMCs on TNFa-stimulated (black bars) or untreated (gray) endothelial cells treated
with Ino-C2-PAF were determined in flow chamber assays. The bars depict average values from three independent experiments (±SEM). (c) Complementary
PBMCs were treated with Ino-C2-PAF for 2 hours. Rolling and firm adhesions on TNFa-stimulated endothelial cells were assessed in the flow chamber.
The bars depict averages from three independent experiments (±SEM). *Po0.05.
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the number of adherent PBMCs was reduced by 72% (Po0.05
in both cases compared with untreated endothelial cells by the
two-sided Student’s t-test; Figure 4c).
Ino-C2-PAF alleviates skin inflammation in
hK.5.TGFb1-transgenic mice and in c-Jun/JunB-deficient mice
We performed in vivo experiments with two complementary
mouse models of psoriasis, namely, mice with transgenic
expression of latent human transforming growth factor-b1
(K5.hTGFb1-transgenic mice (Li et al., 2004)) and mice with
inducible epidermal deletion of JunB/c-Jun (Zenz et al., 2005),
both with a proven pathogenic and therapeutic role of
dysregulated vascular functions (Scho¨nthaler et al., 2009;
Zibert et al., 2011).
When K5.hTGFb1-transgenic mice (two independent
experiments with group sizes of n¼3–4 mice and n¼ 5 mice,
respectively) were injected intraperitoneally at 2-day intervals
with Ino-C2-PAF (30 mg kg1), we observed a marked allevia-
tion of the inflammatory phenotype (two right photographs in
Figure 5a; arrows indicate inflammatory sites on the ears,
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Figure 5. Ino-C2-PAF alleviates psoriasis-like skin lesions in K5.hTGFb1-transgenic mice. (a) Wild-type and K5.hTGFb1 mice received intraperitoneal injections
with vehicle or Ino-C2-PAF (30 mg kg1, end of day (e.o.d.)) for 14 days (total of n¼8–9 mice for each treatment modality). Arrows highlight inflammatory sites.
(b) Wild-type (n¼7) and K5.hTGFb1 mice (n¼ 7) were untreated (gray, n¼ 3 per genotype) or treated with Ino-C2-PAF (30 mg kg1 e.o.d., black, n¼ 4 mice per
genotype). Values represent the means (±SD). *Po0.05, ***Po0.001. c) The weight of all mice (black, Ino-C2-PAF treated; gray, untreated) was monitored.
Values represent means (±SD). *Po0.05, **Po0.01, ***Po0.001. (d) Trunk skin of mice from all treatment groups was stained by hematoxylin and eosin (H&E)
(upper row, epidermal acanthosis, and hyperkeratosis, inflammatory infiltrate), Giemsa (middle row, mast cells), and immunohistochemistry detecting CD31
(bottom row, cutaneous vascularization). Scale bar¼ 50mm.
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eyelids, snout, and feet). There were no overt side effects
(Figure 5a). A ‘‘clinical’’ score assessing erythema, scaling,
alopecia, and size of affected areas (Scho¨n et al., 1997; Zibert
et al., 2011) quantitatively confirmed the disease progression
in vehicle-treated K5.hTGFb1-transgenic mice, while the
disease process was halted in mice receiving Ino-C2-PAF
(Po0.001 after 14 days of treatment; Figure 5b). Of note, in all
K5.hTGFb1-transgenic mice treated with Ino-C2-PAF the
heavily inflamed and stiff skin became considerably softer
and more supple to the touch, an observation that is difficult to
quantitate but was quite striking. In addition, Ino-C2-PAF-
treated K5.hTGFb1-transgenic mice gained weight signifi-
cantly more rapidly compared with their vehicle-treated
counterparts (Po0.001; Figure 5c).
These macroscopic findings were supported by histological
analyses (Figure 5d). Although the overall microscopic phe-
notype in wild-type control animals was not altered indicating
the lack of adverse effects, Ino-C2-PAF clearly reversed the
epidermal acanthosis (thickening of viable cell layers) in
K5.hTGFb1-transgenic mice (Figure 5d). Morphometric ana-
lyses revealed an average epidermal thickness of trunk skin
from vehicle-treated K5.hTGFb1-transgenic mice of 24.4mm
(±4.9 SEM), whereas the respective value in diseased mice
treated with Ino-C2-PAF was only 19.5mm (±3.7 SEM;
Po0.05). In addition, Ino-C2-PAF decreased the inflammatory
infiltrate including CD4þ and CD8þ T cells (Supplementary
Figure S2 online) as well as mast cells (visualized by Giemsa
staining, Figure 5d). Compared with vehicle-treated control
mice, mice treated with Ino-C2-PAF showed significantly
reduced numbers of cutaneous CD4þ T cells (178 per mm
(±62) in vehicle-treated control mice vs. 67 per mm (±24) in
Ino-C2-PAF-treated mice, Po0.001), CD8þ T cells (69 per
mm (±33) vs. 18 per mm (±10), Po0.01), and Mac-1-
expressing macrophages and granulocytes (138 per mm (±41)
vs. 51 per mm (±20), Po0.01). Finally, the pathologic hyper-
vascularization in K5.hTGFb1-transgenic mice was reversed in
mice treated with Ino-C2-PAF, as detected by staining of
CD31 (a reliable marker for blood vessels especially in the
context of angiogenesis). In fact, density and size of cutaneous
blood vessels in K5.hTGFb1-transgenic mice treated with
Ino-C2-PAF were similar to those in wild-type mice (Figure 5d).
The therapeutic efficacy of Ino-C2-PAF achieved in
K5.hTGFb1-transgenic mice was confirmed in an independent
second model: JunB/c-Jun-deficient mice developed chronic
inflammatory and destructive lesions on the ears.
When JunB/c-Jun-deficient mice were injected every other
day for 3 weeks with 30 mg kg 1 of Ino-C2-PAF or were left
untreated, the condition of the control mice worsened,
whereas the disease progression was halted by Ino-C2-PAF
(Figure 6a). Although the initial average ‘‘ear scores’’ were
1.72 in the vehicle-treated group (n¼8 mice) and 1.81 in Ino-
C2-PAF-treated animals (n¼ 8 mice), the vehicle-treated mice
worsened to an average score of 2.22 while the score of Ino-
C2-PAF-treated mice improved to 1.12 (Po0.05 from day 14;
Figure 6b). Similar to K5.hTGFb1-transgenic mice, the JunB/c-
Jun-deficient mice which had received Ino-C2-PAF gained
weight significantly more rapidly as compared with the
controls (average weight gain by the end of the treatment
period was 2.2% in untreated mice vs. 10.4% in Ino-C2-PAF-
treated mice; Po0.01; Figure 6c). Again, the macroscopic
findings were confirmed by histopathological analyses
(Figure 6d).
DISCUSSION
Ino-C2-PAF realizes a quite unique therapeutic principle,
namely, interference with cellular lipid membranes (Arthur
and Bittman, 1998; Wieder et al., 1999; Danker et al., 2010).
This mode of action, which has only recently entered the stage
of anti-inflammatory therapies, affects a number of signaling
processes relevant for both cell proliferation and inflamma-
tion. Indeed, the anti-proliferative capacity and the transcrip-
tional impact of Ino-C2-PAF on genes associated with
immunity and inflammation has been shown in immor-
talized keratinocytes (Gajate and Mollinedo, 2001; Fischer
et al., 2006; Mollinedo et al., 2011). Similar results have been
reported for the structurally related edelfosine (Zerp et al.,
2008). However, although this general mode of action is
shared by Ino-C2-PAF and other alkylated phospholipids
(Arthur and Bittman, 1998; Wieder et al., 1999; Fischer et al.,
2006; Danker et al., 2010), the direct toxicity of Ino-C2-PAF is
distinctly lower than that of chemically related compounds
(Fischer et al., 2006; Danker et al., 2010). We present to our
knowledge previously unreported evidence that Ino-C2-PAF
exerts a profound functional impact on endothelial cells and on
PBMCs in vitro and in vivo. In particular, Ino-C2-PAF induced
apoptosis and inhibited dynamic interactions with lymphocytes
in TNFa-stimulated endothelial cells, and it alleviated chronic
inflammatory skin changes in two complementary murine
models of psoriasis.
Several common inflammatory disorders including psoria-
sis, Crohn’s disease, and rheumatoid arthritis share a complex
pathogenesis that comprises a TNFa-governed microenviron-
ment within the respective inflamed tissues. This impact of this
particular inflammatory milieu on vascular endothelial cells is
associated on one hand with proliferation and formation of
new blood vessels (angiogenesis) and on the other with
activation and altered differentiation of endothelial cells
(Chua and Arbiser, 2009; Marrelli et al., 2011). Strikingly,
induction of apoptosis by Ino-C2-PAF could only be observed
in TNFa-stimulated but not in vehicle-treated endothelial
cells. It is conceivable that TNFa-mediated activation shifts
endothelial cells into a distinctly susceptible state for apoptosis
induction by Ino-C2-PAF. Indeed, this hypothesis is supported
by a recently discovered mechanistic link: on one hand, TNFa
induces apoptosis via TNF-R1 and consecutive signaling
through fas-associated death domain (Chen and Goeddel,
2002), and, on the other, Ino-C2-PAF activiates fas-asso-
ciated death domain-dependent apoptosis (von Haefen
et al., 2011).
Inflammatory states also include upregulation of endothelial
adhesion molecules crucial for the recruitment of immune
cells (Boer et al., 1994). These receptors include VCAM-1,
ICAM-1, and E-selectin, which mediate leukocyte rolling and
firm adhesive interactions between the two cell types (Alon
et al., 1995; Zo¨llner et al., 1997; Celli et al., 2006; Allingham
et al., 2007).
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Interference of Ino-C2-PAF with TNFa-induced endothelial
adhesion molecule expression occurs partly on the transcrip-
tional level, as evinced by decreased messenger RNA levels in
treated cells. This regulation by Ino-C2-PAF cannot be
attributed to some general inhibition of transcription, as
several other TNFa-regulated gene products including adhe-
sion receptors, cytokines, and chemokines were not affected.
On the basis of previous results with the related compound
edelfosine, it is conceivable that transcriptional regulation by
Ino-C2-PAF is effected through interference with lipid rafts
and the phosphatidylcholine-dependent generation of second
messengers. However, other ways of adhesion receptor
regulation cannot be formally excluded. At least in freshly
isolated human lymphocytes, where changes in surface
receptors were detected after 2 hours of treatment, an entirely
transcriptional regulation appears unlikely.
Besides effects on endothelial cells, Ino-C2-PAF decreased
lymphocyte adhesion molecules in vitro and in vivo. The net
result was profound impairment of rolling and adhesion of
PBMCs on endothelial cells. Thus, the final net outcome was
remarkably similar to that of established anti-psoriatic drugs
such as TNFa-directed biologics (Settles et al., 2001; Arijs
et al., 2011; Lockmann and Scho¨n, 2013) or fumaric acid
esters (Loewe et al., 2002; Wallbrecht et al., 2011).
As a proof-of-concept, Ino-C2-PAF markedly alleviated the
psoriatic phenotype in two complementary mouse models,
which feature some advantages with respect to research into
therapies against psoriasis (Scho¨n, 2008): both models,
Vehicle VehicleIno-C2-PAF Ino-C2-PAF
H&E
Giemsa
In
o-
C2
-P
AF
Co
nt
ro
l
18
6
0
12
Ino-C2-PAF
**
Control
Ch
an
ge
 in
 w
ei
gh
t (%
)
Cre– /wild type Cre+ /JunB/c-Jun-/-
5
0
4
3
1 7 14 21
Days
2
1
*
*
M
ea
n 
se
ve
rit
y 
sc
or
e 
of
 e
ar
s
50 μm 50 μm 50 μm 50 μm
50 μm50 μm50 μm50 μm
Figure 6. Ino-C2-PAF ameliorates hyperproliferative inflammatory skin changes in JunB/c-Jun-deficient mice. (a) JunB/c-Jun-deficient mice received
intraperitoneal injections with Ino-C2-PAF (30 mg kg 1 end of day for 21 days; n¼ 8 mice) or remained untreated (n¼9). Arrows indicate inflammatory
deformities, which were halted in the Ino-C2-PAF-treated animals. (b) Mice were weighed at the beginning and at the end of the 21-day treatment period. Bars
represent average weight changes (±SD; gray, untreated; black, Ino-C2-PAF treated). **Po0.01. (c) A modified score was used to assess inflammatory ear changes
in control (gray) and Ino-C2-PAF-treated mice (black). *Po0.05. (d) Ears of JunB/c-Jun-deficient mice were stained by hematoxylin and eosin (H&E) (upper row)
and Giemsa (bottom row) to demonstrate the alleviation of hyperproliferative inflammatory skin changes by Ino-C2-PAF. Photomicrographs of representative
samples are shown. Scale bar¼ 50mm.
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K5.hTGFb1-transgenic and JunB/c-Jun-deficient mice, show a
hyperproliferative, acanthotic, and hyperkeratotic epidermis
in association with a mixed inflammatory infiltrate in a Th1-
weighted milieu with elevated levels of TNFa (Li et al., 2004;
Zenz et al., 2005). In addition, in both models a significant
pathogenic and therapeutic role of the vascular system
without a primary (genetic) vascular defect has been
demonstrated (Scho¨nthaler et al., 2009; Zibert et al., 2011).
The improvement of the condition becomes clearly evident
when treated animals are compared with control mice on both
the macroscopic and microscopic level, as some histomorpho-
logical ameliorations become apparent even if the macroscopic
score does not decrease (yet). Of note, the inflammatory
disorder in both mouse models is not limited to the skin, but
rather affects other organ systems as well. Although there are
clear differences between mouse models and human psoriasis,
the latter notion is in line with our current concept that human
psoriasis is a systemic inflammatory disorder that predisposes to
a number of associated comorbid diseases (Boehncke et al.,
2010; Davidovici et al., 2010; Reich, 2012). It is, therefore,
particularly interesting that treatment with Ino-C2-PAF not only
alleviated the severe skin inflammation but also led to
accelerated weight gain in both mouse strains.
Considering the known activity of Ino-C2-PAF on functions
of different cell types, it is likely that interference with
endothelial functions and leukocyte recruitment are not the
only aspects resulting in the alleviation of the psoriasiform
phenotypes in the two animal models. It is conceivable that
other effects, such as inhibition of keratinocyte proliferation,
also contribute to the overall ‘‘clinical’’ activity. In any case,
the impact on endothelial functions is likely involved in this
net effect, and Ino-C2-PAF or related compounds may
be a worthwhile addition to our current anti-inflammatory
therapeutic armamentarium.
MATERIALS AND METHODS
Cells and cell culture
Human umbilical vein endothelial cells (HUVEC; Lonza, Basel,
Switzerland) were grown to confluency in endothelial cell growth
medium containing 2% fetal calf serum (FCS). Cells were treated
with Ino-C2-PAF at different concentrations for 24 hours. In the last
4 hours, they were stimulated with recombinant human TNFa
(25 ng ml 1; ImmunoTools, Friesoythe, Germany). Nonactivated
(vehicle treated) cells served as control.
PBMCs were isolated from heparinized venous blood of healthy
volunteers (experiments with human cells were approved by the local
ethics committee) by Ficoll density gradient centrifugation (Ficoll-
Paque Plus; GE Healthcare, Freiburg, Germany). Cells labeled for
15 minutes with 2mM carboxyfluorescein diacetate N-succinimidyl
ester (Invitrogen, Carlsbad, CA) dissolved in Hank’s Balanced Salt
Solution (Invitrogen) were used for flow chamber experiments.
PBMCs treated with Ino-C2-PAF or vehicle were cultured in Roswell’s
Park Memorial Institute containing 5% glutamine, 50mM b-mercap-
toethanol, and 1% FCS at 37 1C and 5% CO2.
Flow cytometry
Endothelial cells were seeded at a density of 8 104 cells per well
in 12-well plates. After the treatment, cells were washed with
phosphate-buffered saline (PBS), disaggregated with Accutase,
and resuspended in PBS containing 5% antibody-serum (Sigma-
Aldrich, St. Louis, MO). Antibodies directed against VCAM-1
(ImmunoTools), E-selectin (antibodies online, Aachen, Germany),
and ICAM-1 (DAKO, Hamburg, Germany) were used. Isotype-
matched mouse IgG served as control.
PBMCs cultured in Roswell’s Park Memorial Institute containing
5% glutamine, 50mM b-mercaptoethanol, and 1% FCS at 37 1C and
5% CO2 were treated with Ino-C2-PAF at different concentrations
of up to 30mM for 2 hours. The cells were then washed with PBS
and resuspended with PBS containing 5% antibody-Serum (Sigma-
Aldrich). Samples were analyzed with a FACSCanto II and the
FACSDiva software (Becton Dickinson, Heidelberg, Germany).
Immunofluorescence microscopy
Endothelial cells were plated at a density of 3 104 cells per well in
eight-well chamber slides, where they were stimulated with TNFa
(25 ng ml 1) and treated with Ino-C2-PAF at concentrations indicated
in the respective figures. The cells were then washed two times with
cold PBS, fixed with ice-cold methanol, and blocked with PBS
containing 5% FCS. Antibodies were diluted in PBS containing
2.5% FCS.
Flow chamber experiments
Endothelial cells (105 cells) were seeded on thermanox coverslips
(22 60 mm; ThermoScientific, Langenselbold, Germany). After treat-
ment with Ino-C2-PAF at different concentrations and immediately
before the experiment, the coverslips were placed into the flow
chamber. PBMCs were perfused through the flow chamber (Perfusor,
WPI, Sarasota, FL) at an average of 106 cells ml 1 with a constant
flow rate of 1.12 ml per hour.
In vivo experiments with K5.hTGFb1-transgenic and JunB/c-Jun-
deficient mice
Mice with transgenic epidermal expression of latent human
transforming growth factor-b1 (K5.hTGFb1 mice in an ICR(CD-1)
genetic background; (Li et al., 2004)) and mice with inducible
epidermal deletion of JunB and c-Jun (JunB/c-Jun-deficient mice
in a C57BL/6 genetic background; (Zenz et al., 2005)) were bred
and treated as described in the original publications. The respective
wild-type ICR(CD-1) and C57BL/6 mice served as controls.
Mice were used at an age of 8–10 weeks. They were left untreated,
and were injected intraperitoneally at 2-day intervals for up to
3 weeks (as specified in the text) either with vehicle (sterile
physiological NaCl solution (0.9%)) or with Ino-C2-PAF at doses of
30 mg kg 1. All animal experiments were approved by the local
authorities.
Histochemistry and immunohistochemistry
Paraffin-embedded tissue sections of 3mm thickness were stained
with hematoxylin and eosin or Giemsa according to standard
protocols. Immunohistochemistry was performed on 5-mm thick
cryosections.
Statistics
Data are displayed as mean (±SD or ±SEM as indicated). P-values
were determined using the two-tailed Student’s t-test. Pr0.05 was
considered statistically significant.
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